GE's EHR gremlin may prohibit meaningful use attestation

Eligible hospitals that have already attested to meaningful use in 2011 through the Medicare EHR Incentive Program via GE Healthcare IT’s Centricity Practice Solution and Centricity EMR may want to think twice before closing the books on that initiative.

The Barrington, Ill.-based company recently became aware of inaccuracies with reports in certain tools that may affect customers who have attested or are currently planning to attest for meaningful use, according to a letter from Michael Friguletto, vice president and general manager of GE Healthcare IT.

"GE Healthcare is moving quickly to correct these inaccuracies, and we expect to have the affected reports fixed no later than the end of November,” Friguletto wrote.

The inaccuracies identified may affect the results obtained from the Crystal Reports or Medical Quality Improvement Consortium reporting tools for meaningful use, according to the letter, which noted that the inaccuracies affect some of the meaningful use reporting measures. However, the underlying clinical data and logic of the EMR system remain sound.

“If you have already attested in 2011, we recommend that you run the reports again for your particular attestation period after we provide the updates,” Friguletto wrote. “If your results are different from those used for attestation, you may need to evaluate if you have still cleared all applicable meaningful use thresholds for the original period or would meet the thresholds for all applicable measures (not only those that may have changed in the initial reporting period) for a later reporting period in 2011.”

He added that GE is working with the Centers for Medicare & Medicaid Services to identify what stakeholders may need to do if the data used to support attestation have changed. Eligible professionals may attest with 2011 data until Feb. 29, 2012, he added.

“If you have not yet attested and you use only GE Healthcare's reports for your meaningful use attestation, we recommend that you delay your attestation until the updated reports are released,” Friguletto concluded.

GE Healthcare additionally released a series of immediate steps needed to take on three specific measures for progress towards meaningful use that is available here.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.